NCT06114940 2026-03-05
PLUTO
Jinling Hospital, China
Phase 2 Terminated
Clinical Trials
9 trialsNCT04866836 2025-03-21
A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Terminated
NCT03991130 2025-02-06
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
Phase 2 Terminated
NCT04310397 2024-10-30
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03207867 2024-10-09
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis
Phase 2 Terminated
NCT04323436 2024-10-09
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
Novartis
Phase 2 Terminated
NCT03291054 2024-06-11
Epacadostat and Pembrolizumab in Patients With GIST
Columbia University
Phase 2 Terminated
NCT04430036 2024-04-04
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT01420965 2019-07-10
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Augusta University
Phase 2 Terminated